奥沙利铂+替吉奥化疗方案在高龄晚期胃癌患者治疗中的应用

Research on application of oxaliplatin + S-1 chemotherapy in the treatment of elderly patients with gastric cancer

目的:研究奥沙利铂+替吉奥化疗方案在高龄晚期胃癌患者治疗中的应用效果。方法:选择2011年8月至2013年8月在我院接受化疗的高龄晚期胃癌患者68例,分为实验组(34例)与对照组(34例),实验组以奥沙利铂+替吉奥方案化疗,对照组以FOLFOX6方案化疗,观察两组患者近期疗效、临床受益反应、免疫功能及不良反应。结果:经2个周期的化疗,实验组RR(61.76%)高于对照组RR(35.29%),存在显著统计学差异(P<0.05);实验组受益率(61.76%)显著高于对照组受益率(35.29%),存在显著统计学差异(P<0.05)。两组患者化疗后CD3^+、CD8^+以及CD19^+等免疫功能指标与化疗前比较(P>0.05);两组患者化疗后CD4^+与CD4^+/CD8^+与化疗前组内比较(P<0.05);两组患者化疗后CD4^+组间比较(P<0.05),均存在显著统计学差异。实验组Ⅰ-Ⅱ度不良反应发生率均低于对照组,两组间除恶心呕吐发生率存在统计学差异(P<0.05)外,其他不良反应均无统计学差异(P>0.05)。结论:奥沙利铂+替吉奥化疗方案疗效显著,不良反应发生率低,适合耐受程度较差的高龄晚期胃癌患者的治疗。

Objective：To study the effect of oxaliplatin ＋ S - 1 chemotherapy in the treatment of elderly patients with gastric cancer. Methods ： Elderly patients with gastric cancer treated with chemotherapy 68 cases were divided in-to experimental group（34 cases） and control group（34 cases）. The experimental group were treated with oxaliplatin ＋ S - 1 chemotherapy, the control group with chemotherapy FOLFOX6 scheme. Results ： After 2 cycles of chemothera-py, in experiment group RR（61.76% ） , higher than the controls（ 35. 29% ） , （ P 〈 0. 05 ） . Experimental group benefit benefit rate（61.76% ） was significantly higher than control group（ 35. 29% ） 〈 0. 05. Two groups of patients afterchemotherapy CD3 ＋,CDg ＋, CD19 ＋ immune function indexes（ P 〉 0. 05 ） . CD4 ＋ and CD4 ＋ /CD8 ＋ compared with be-fore chemotherapy（ P 〈 0. 05 ） . I - II degree side effects were lower than the control group （P 〈 0 . 05） , the other side effects were no statistical difference （P 〉0. 05） . Conclusion ： Oxaliplatin ＋ S - 1 chemotherapy effect is good with low incidence of adverse reaction, suitable for elderly patients with gastric cancer.